We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
-16.23%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
-$532M
(-25%)
Cap. Flow
-$18.1M
Cap. Flow
% of AUM
-1.15%
Top 10 Holdings %
Top 10 Hldgs %
64.59%
Holding
44
New
6
Increased
6
Reduced
3
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$35M |
| 2 |
Cullinan Oncology
CGEM
|
+$29.4M |
| 3 |
Zura Bio
ZURA
|
+$24.6M |
| 4 |
Spyre Therapeutics
SYRE
|
+$17.3M |
| 5 |
PCSC
Perceptive Capital Solutions
PCSC
|
+$7.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HLVX
HilleVax
HLVX
|
+$34.5M |
| 2 |
MRUS
Merus
MRUS
|
+$25.5M |
| 3 |
Celcuity
CELC
|
+$21M |
| 4 |
Immatics
IMTX
|
+$18.4M |
| 5 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.52% |
| 2 | Financials | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arvinas
ARVN
$518M
| $16.7M | 1.06% |
627,788
| – | – |
|
27
Aquestive Therapeutics
AQST
$463M
| $14.4M | 0.92% |
5,555,555
| – | – |
|
28
Century Therapeutics
IPSC
$364M
| $13.7M | 0.88% |
5,389,259
+1,984,126
| +58% | +$6.27M |
|
29
Cabaletta Bio
CABA
$437M
| $11.7M | 0.75% |
1,563,952
| – | – |
|
30
Trevi Therapeutics
TRVI
$2.59B
| $10.2M | 0.65% |
3,422,637
-38
| -0% | -$106 |
|
|
ADVM
31
DELISTED
Adverum Biotechnologies
ADVM
| $10.1M | 0.64% |
1,467,048
-89,371
| -6% | -$831K |
|
|
PCSC
32
DELISTED
Perceptive Capital Solutions
PCSC
| $7.54M | 0.48% |
+750,000
| New | +$7.55M |
|
33
Tenaya Therapeutics
TNYA
$161M
| $4.82M | 0.31% |
1,555,556
| – | – |
|
|
ORKA
34
Oruka Therapeutics
ORKA
$5.82B
| $3.32M | 0.21% |
+72,198
| New | +$2.88M |
|
|
CASI
35
DELISTED
CASI Pharmaceuticals
CASI
| $614K | 0.04% |
+111,686
| New | +$347K |
|
|
36
Celcuity
CELC
$4.21B
| – | – |
-970,000
| Closed | -$21M |
|
37
CG Oncology
CGON
$6.28B
| – | – |
-350,000
| Closed | -$15.4M |
|
38
EyePoint Inc
EYPT
$1.03B
| – | – |
-250,000
| Closed | -$5.17M |
|
|
HLVX
39
DELISTED
HilleVax
HLVX
| – | – |
-2,075,000
| Closed | -$34.5M |
|
|
40
Immatics
IMTX
$1.18B
| – | – |
-1,750,000
| Closed | -$18.4M |
|
|
LYRA
41
DELISTED
LYRA THERAPEUTICS INC
LYRA
| – | – |
-51,522
| Closed | -$16M |
|
42
Mineralys Therapeutics
MLYS
$2.25B
| – | – |
-555,554
| Closed | -$7.17M |
|
43
Olema Pharmaceuticals
OLMA
$1B
| – | – |
-77,042
| Closed | -$872K |
|
|
SLRN
44
DELISTED
ACELYRIN
SLRN
| – | – |
-937,113
| Closed | -$6.33M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q2 2024 Portfolio in Review
As of Q2 2024, VR Adviser held 44 positions worth $1.57B, down 25% from $2.1B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
VR Adviser's Q2 2024 filing shows 6 new, 6 increased, 3 reduced and 9 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was HilleVax, an estimated $34.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.
- VR Adviser's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
- VR Adviser added most to Spyre Therapeutics in Q2 2024, an estimated $17.3M increase.
- VR Adviser's biggest Q2 2024 reduction was Merus, cutting an estimated $25.5M.
- VR Adviser fully exited HilleVax in Q2 2024, selling an estimated $34.5M.
- VR Adviser's ten largest holdings make up 65% of its $1.57B portfolio in Q2 2024.
- VR Adviser opened 6 new positions and closed 9 in Q2 2024.
- VR Adviser's portfolio value fell 25% quarter-over-quarter to $1.57B.
Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.